Sullivan Mark's Form 4 filing
Definium Therapeutics, Inc. (DFTX) · filed Mar 26, 2026
- Accession no.
- 0001193125-26-126827
- Filed
- Mar 26, 2026
- Trade date
- Mar 25, 2026
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 1 non-derivative transaction. Open-market sales total $197.7K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Sullivan MarkCIK 0001331843 | Officer (Chief Legal Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 25, 2026 | Common Shares | SSaleDisposed | −10,702 | $18.47F2 | −$197,665.94 | 271,079 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The reported price is a weighted average sales price. These shares were sold in multiple transactions on March 25, 2026 at prices ranging from $18.36 to $18.80. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.